Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10296 in EGFR TKI-refractory advanced NSCLC
CTR20171268Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Oct 2017; status: active.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20171268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171268.